The dementia vaccine some of us are taking without realising

Key Points:

• Dementia currently affects over 55 million people worldwide, with numbers expected to nearly triple by 2050, and existing treatments offer limited symptom relief without stopping disease progression.
• A natural experiment in Wales revealed that the shingles vaccine reduced dementia risk by 20%, a finding replicated in several countries, suggesting that certain vaccines may prevent or slow dementia.
• Research indicates that multiple vaccines—including those for shingles, tuberculosis (BCG), influenza, and others—are associated with lower dementia risk, possibly due to their ability to modulate immune response and reduce neuroinflammation.
• Emerging theories propose that dementia may result from systemic immune dysfunction and chronic inflammation triggered by infections, rather than solely from toxic protein buildup, prompting a shift in understanding and treatment approaches.
• New vaccine developments targeting tau and beta-amyloid proteins, combined with early diagnosis and multi-target therapies, offer hope for more effective dementia prevention and treatment, though safety and efficacy challenges remain.